CENTER OF DRUG DISCOVERY

OUT-LICENSING PARTNER

(To be disclosed later)

Founded on May 8, 2020
By the Institute of Cancer & Basic Medicine,
   Chinese Academy of Sciences and Lynk
   Pharmaceuticals

IN-LICENSING PARTNERS

Lynk successfully in-licensed RAS inhibitors
with novel mechanism of action (global rights)
from a Kobe university (Japan) & RIKEN research
institute (Japan) on July 16th, 2020